dwinnex.com

TherapeuticsMD, Inc. [NASDAQ:TXMD]: Analyst Rating and Earnings

Stock market traders oftentimes pay a lot of attention to what top analysts say regarding a potential investment. Regarding TherapeuticsMD, Inc. [TXMD], the latest average analyst recommendation we can see is from the quarter closing in December. On average, stock market experts give TXMD an Outperform rating. Its stock price has been found in the range of 3.51 to 7.66. This is compared to its latest closing price of $5.44.

Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for TherapeuticsMD, Inc. [TXMD] is sitting at 1.88. This is compared to 1 month ago, when its average rating was 1.62.

For the quarter ending in Dec-18 TherapeuticsMD, Inc. [TXMD] generated $0.01 billion in sales. That’s 1.70% higher than the average estimate of $0.01 billion as provided by Wall Street analysts. The three indicators above suggest that overall, this stock is demonstrating a mixed bag of positive appeal and some drawbacks, making it a somewhat risky investment that also has the potential to generate high ROI in the long run.

Pay attention for this company’s financial results, of which the next release is scheduled to happen on Thu 2 May (In 64 Days).

Fundamental Analysis of TherapeuticsMD, Inc. [TXMD]

Now let’s turn to look at profitability: with a current Operating Margin for TherapeuticsMD, Inc. [TXMD] sitting at -462.69 and its Gross Margin at +83.01.

This company’s Return on Total Capital is -60.32, and its Return on Invested Capital has reached -59.80%. Its Return on Equity is -59.77, and its Return on Assets is -53.85. These metrics suggest that this TherapeuticsMD, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.

What about valuation? This company’s Enterprise Value to EBITDA is -9.31. The Enterprise Value to Sales for this firm is now 75.17. TherapeuticsMD, Inc. [TXMD] has a Price to Book Ratio of 10.06.

Shifting the focus to workforce efficiency, TherapeuticsMD, Inc. [TXMD] earns $96,981 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 3.80 and its Total Asset Turnover is 0.12. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 10.36 and its Current Ratio is 10.48. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.

TherapeuticsMD, Inc. [TXMD] has 224.22M shares outstanding, amounting to a total market cap of $1.28B. Its stock price has been found in the range of 3.51 to 7.66. At its current price, it has moved by -25.59% from its 52-week high, and it has moved 62.62% from its 52-week low.

This stock’s Beta value is currently 2.05, which indicates that it is more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 58.62. This RSI score is good, suggesting this stock is neither overbought or oversold.

Conclusion: Is TherapeuticsMD, Inc. [TXMD] a Reliable Buy?

TherapeuticsMD, Inc. [TXMD] stock is presenting a less attractive investment opportunity when compared to similarly-sized corporations in the same industry. The price performance of these shares has not shown much promise, and the financial results that this company has recently delivered present a highly risky investment.